Compare Global X NASDAQ 100 Covered Call ETF (QYLD) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X NASDAQ 100 Covered Call ETF vs Tango Therapeutics Inc. — how do they compare? Global X NASDAQ 100 Covered Call ETF trades at $18.64 (market cap $8.54B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Global X NASDAQ 100 Covered Call ETF is far larger — about 2.3× Tango Therapeutics Inc.'s market cap, and Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X NASDAQ 100 Covered Call ETF for 51 Days and Tango Therapeutics Inc. for 0 Days on average.
| QYLD | TNGX | |
|---|---|---|
Market Cap | $8.54B | $3.75B |
Volume | 2,383,712 | 9,619,106 |
Sector | Income / Options Overlay | Health |
52-Week High | $18.69 | $32.90 |
52-Week Low | $16.70 | $7.50 |
Typical Hold Time | 51 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QYLD trades at $18.69, showing minimal daily movement with a 0.05% gain. The ETF's technical outlook is bullish based on moving averages, but oscillators signal caution with RSI levels above 75 indicating overbought conditions. Recent news highlights its high monthly dividend yield but raises concerns about long-term capital erosion and capped upside due to its covered call strategy, with distributions consistently at $0.18 per share.
The outlook for QYLD is mixed; it offers attractive income with a high yield, appealing for investors seeking monthly cash flow. However, risks include limited growth potential, declining option premiums, and potential tax reclassification of dividends. Analyst sentiment is divided, with some upgrades citing yield attractiveness but others warning of principal erosion over time.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
